You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):控股子公司與Expedition簽訂《許可協議》

格隆匯8月11日丨復星醫藥(600196.SH)公佈,公司控股子公司復星醫藥產業與Expedition簽訂《許可協議》,復星醫藥產業授予Expedition除中國境內及港澳地區以外的全球範圍、許可領域內開發、生產及商業化在研產品XH-S004的權利。本次合作後,本集團仍擁有許可產品於中國境內及港澳地區的開發、生產及商業化權利。

XH-S004爲本集團擁有自主知識產權的小分子口服DPP-1抑制劑,其通過抑制DPP-1及其激活的中性粒細胞絲氨酸蛋白酶降低炎症反應,從而阻斷感染惡性循環及由此導致的氣道結構損傷。該在研藥品的潛在適應症包括非囊性纖維化支氣管擴張症、慢性阻塞性肺疾病等。截至本公告日期(即2025年8月11日),XH-S004用於治療非囊性纖維化支氣管擴張症於中國境內處於II期臨牀試驗階段、用於治療慢性阻塞性肺疾病於中國境內處於Ib期臨牀試驗階段。

(1)根據約定,Expedition將就本次合作向復星醫藥產業支付至多12,000萬美元不可退還的首付款、開發及監管里程碑付款,具體包括:①首付款1,700萬美元;②根據許可產品於許可區域的臨牀試驗及上市進展等,支付至多10,300萬美元的開發及監管里程碑款項。(2)此外,基於許可產品於許可區域的年度淨銷售額(定義依約定)達成情況,由Expedition向復星醫藥產業依約支付至多52,500萬美元的銷售里程碑款項。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account